PGDx machine learning approach outperforms existing mutation detection methods in study

Personal Genome Diagnostics, Inc. (PGDx), a leader in cancer genomics, today announced that its machine learning based technology, CerebroTM, outperformed existing methods to identify tumor-specific, or somatic mutations, enabling more accurate NGS clinical test results.

Top News

Ain't No God; don't even think about theism

UnFox News: not a propaganda arm of the Republican party